Therapeutic Effects of Melatonin Receptor Agonists on Sleep and Comorbid Disorders
AbstractSeveral melatonin receptors agonists (ramelteon, prolonged-release melatonin, agomelatine and tasimelteon) have recently become available for the treatment of insomnia, depression and circadian rhythms sleep-wake disorders. The efficacy and safety profiles of these compounds in the treatment of the indicated disorders are reviewed. Accumulating evidence indicates that sleep-wake disorders and co-existing medical conditions are mutually exacerbating. This understanding has now been incorporated into the new Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5). Therefore, when evaluating the risk/benefit ratio of sleep drugs, it is pertinent to also evaluate their effects on wake and comorbid condition. Beneficial effects of melatonin receptor agonists on comorbid neurological, psychiatric, cardiovascular and metabolic symptomatology beyond sleep regulation are also described. The review underlines the beneficial value of enhancing physiological sleep in comorbid conditions. View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Laudon, M.; Frydman-Marom, A. Therapeutic Effects of Melatonin Receptor Agonists on Sleep and Comorbid Disorders. Int. J. Mol. Sci. 2014, 15, 15924-15950.
Laudon M, Frydman-Marom A. Therapeutic Effects of Melatonin Receptor Agonists on Sleep and Comorbid Disorders. International Journal of Molecular Sciences. 2014; 15(9):15924-15950.Chicago/Turabian Style
Laudon, Moshe; Frydman-Marom, Anat. 2014. "Therapeutic Effects of Melatonin Receptor Agonists on Sleep and Comorbid Disorders." Int. J. Mol. Sci. 15, no. 9: 15924-15950.